The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells
Open accessAbstract
A key mechanism of tumor resistance to immune cells is mediated by expression of peptide-loaded HLA-E in tumor cells, which suppresses natural killer (NK) cell activity via ligation of the NK inhibitory receptor CD94/NKG2A. Gene expression data from approximately 10,000 tumor samples showed widespread HLAE expression, with levels correlating with those of KLRC1 (NKG2A) and KLRD1 (CD94). To bypass HLA-E inhibition, we developed a way to generate highly functional NK cells lacking NKG2A. Constructs containing a single-chain variable fragment derived from an anti-NKG2A antibody were linked to endoplasmic reticulum-retention domains. After retroviral transduction in human peripheral blood NK cells, these NKG2A Protein Expression Blockers (PEBLs) abrogated NKG2A expression. The resulting NKG2Anull NK cells had higher cytotoxicity against HLA-E-expressing tumor cells. Transduction of anti-NKG2A PEBL produced more potent cytotoxicity than interference with an anti-NKG2A antibody and prevented de novo NKG2A expression, without affecting NK cell proliferation. In immunodeficient mice, NKG2Anull NK cells were significantly more powerful than NKG2A+ NK cells against HLA-E-expressing tumors. Thus, NKG2A downregulation evades the HLA-E cancer immune-checkpoint, and increases the anti-tumor activity of NK cell infusions. Because this strategy is easily adaptable to current protocols for clinical-grade immune cell processing, its clinical testing is feasible and warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
Liao, Y., Smyth, G. K., & Shi, W. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt656 · Cited by 27,219
TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells
Li, T., Fan, J., Wang, B., Traugh, N., Chen, Q., Liu, J. S., Li, B., & Liu, X. S. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0307 · Cited by 5,913
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W. D., Tosti, A., Posati, S., Rogaia, D., Frassoni, F., Aversa, F., et al. (2002) · Science · doi:10.1126/science.1068440 · Cited by 3,380
HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C
Braud, V. M., Allan, D. S. J., O'Callaghan, C. A., Söderström, K., D'Andrea, A., Ogg, G. S., Lazetic, S., Young, N. T., Bell, J. I., Phillips, J. H., et al. (1998) · Nature · doi:10.1038/35869 · Cited by 2,227
Miller, J. S., Soignier, Y., Panoskaltsis-Mortari, A., McNearney, S. A., Yun, G. H., Fautsch, S. K., McKenna, D., Le, C., Defor, T. E., Burns, L. J., et al. (2005) · Blood · doi:10.1182/blood-2004-07-2974 · Cited by 1,903
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
Eyquem, J., Mansilla-Soto, J., Giavridis, T., van der Stegen, S. J. C., Hamieh, M., Cunanan, K. M., Odak, A., Gönen, M., & Sadelain, M. (2017) · Nature · doi:10.1038/nature21405 · Cited by 1,831 · cited 1×
“Downregulation of NKG2A might have also been achieved by using modern gene-editing methodologies based on mega-nucleases, TALEN, or CRISPR/Cas9, which have already been applied to genetically modify T lymphocytes (66–69).”
André, P., Denis, C., Soulas, C., Bourbon-Caillet, C., Lopez, J., Arnoux, T., Bléry, M., Bonnafous, C., Gauthier, L., Morel, A., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.014 · Cited by 1,221
NK cells and cancer: you can teach innate cells new tricks
Morvan, M. G., & Lanier, L. L. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.5 · Cited by 1,162
In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target
Manguso, R. T., Pope, H. W., Zimmer, M. D., Brown, F. D., Yates, K. B., Miller, B. C., Collins, N. B., Bi, K., LaFleur, M. W., Juneja, V. R., et al. (2017) · Nature · doi:10.1038/nature23270 · Cited by 1,147
HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A
Lee, N., Llano, M., Carretero, M., Ishitani, A., Navarro, F., López-Botet, M., & Geraghty, D. E. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.9.5199 · Cited by 1,053
Romee, R., Rosario, M., Berrien-Elliott, M. M., Wagner, J. A., Jewell, B. A., Schappe, T., Leong, J. W., Abdel-Latif, S., Schneider, S. E., Willey, S., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf2341 · Cited by 942
Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells
Qasim, W., Zhan, H., Samarasinghe, S., Adams, S., Amrolia, P., Stafford, S., Butler, K., Rivat, C., Wright, G., Somana, K., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaj2013 · Cited by 902
Therapeutic T cell engineering
Sadelain, M., Rivière, I., & Riddell, S. (2017) · Nature · doi:10.1038/nature22395 · Cited by 879
Liu, E., Tong, Y., Dotti, G., Shaim, H., Savoldo, B., Mukherjee, M., Orange, J., Wan, X., Lu, X., Reynolds, A., et al. (2018) · Leukemia · doi:10.1038/leu.2017.226 · Cited by 824
Borrego, F., Ulbrecht, M., Weiss, E. H., Coligan, J. E., & Brooks, A. G. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.5.813 · Cited by 727
Cytokine activation induces human memory-like NK cells
Romee, R., Schneider, S. E., Leong, J. W., Chase, J. M., Keppel, C. R., Sullivan, R. P., Cooper, M. A., & Fehniger, T. A. (2012) · Blood · doi:10.1182/blood-2012-04-419283 · Cited by 684
Mamessier, E., Sylvain, A., Thibult, M.-L., Houvenaeghel, G., Jacquemier, J., Castellano, R., Gonçalves, A., André, P., Romagné, F., Thibault, G., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45816 · Cited by 681
Imai, C., Iwamoto, S., & Campana, D. (2005) · Blood · doi:10.1182/blood-2004-12-4797 · Cited by 659
Self-citationHLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells
Gornalusse, G. G., Hirata, R. K., Funk, S. E., Riolobos, L., Lopes, V. S., Manske, G., Prunkard, D., Colunga, A. G., Hanafi, L.-A., Clegg, D. O., et al. (2017) · Nature Biotechnology · doi:10.1038/nbt.3860 · Cited by 639 · cited 1×
“Upon ligation by peptide-loaded HLA-E, NKG2A trans-duces inhibitory signaling through 2 inhibitory immune-receptor tyrosine-based inhibition motifs, thus suppressing NK cytokine secretion and cytotoxicity (16–18).”
Poirot, L., Philip, B., Schiffer-Mannioui, C., Le Clerre, D., Chion-Sotinel, I., Derniame, S., Potrel, P., Bas, C., Lemaire, L., Galetto, R., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3321 · Cited by 605
Expansion of Highly Cytotoxic Human Natural Killer Cells for Cancer Cell Therapy
Fujisaki, H., Kakuda, H., Shimasaki, N., Imai, C., Ma, J., Lockey, T., Eldridge, P., Leung, W. H., & Campana, D. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3712 · Cited by 595
Self-citationCooley, S., Weisdorf, D. J., Guethlein, L. A., Klein, J. P., Wang, T., Le, C. T., Marsh, S. G. E., Geraghty, D., Spellman, S., Haagenson, M. D., et al. (2010) · Blood · doi:10.1182/blood-2010-05-283051 · Cited by 591
Association of DAP12 with Activating CD94/NKG2C NK Cell Receptors
Lanier, L. L., Corliss, B., Wu, J., & Phillips, J. H. (1998) · Immunity · doi:10.1016/s1074-7613(00)80574-9 · Cited by 559
Torikai, H., Reik, A., Liu, P.-Q., Zhou, Y., Zhang, L., Maiti, S., Huls, H., Miller, J. C., Kebriaei, P., Rabinovitch, B., et al. (2012) · Blood · doi:10.1182/blood-2012-01-405365 · Cited by 528
Profound Coordinated Alterations of Intratumoral NK Cell Phenotype and Function in Lung Carcinoma
Platonova, S., Cherfils-Vicini, J., Damotte, D., Crozet, L., Vieillard, V., Validire, P., André, P., Dieu-Nosjean, M.-C., Alifano, M., Régnard, J.-F., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4179 · Cited by 512
Nilsson, T., Jackson, M., & Peterson, P. A. (1989) · Cell · doi:10.1016/0092-8674(89)90105-0 · Cited by 493
Lazetic, S., Chang, C., Houchins, J. P., Lanier, L. L., & Phillips, J. H. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.11.4741 · Cited by 447
Vales-Gomez, M. (1999) · The EMBO Journal · doi:10.1093/emboj/18.15.4250 · Cited by 384
Llano, M., Lee, N., Navarro, F., García, P., Albar, J. P., Geraghty, D. E., & López-Botet, M. (1998) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199809)28:09<2854::aid-immu2854>3.0.co;2-w · Cited by 382
Cellular Constituents of Immune Escape within the Tumor Microenvironment
Kerkar, S. P., & Restifo, N. P. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-4094 · Cited by 370
Ciurea, S. O., Schafer, J. R., Bassett, R., Denman, C. J., Cao, K., Willis, D., Rondon, G., Chen, J., Soebbing, D., Kaur, I., et al. (2017) · Blood · doi:10.1182/blood-2017-05-785659 · Cited by 345
NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines
van Montfoort, N., Borst, L., Korrer, M. J., Sluijter, M., Marijt, K. A., Santegoets, S. J., van Ham, V. J., Ehsan, I., Charoentong, P., André, P., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.028 · Cited by 333
Chang, Y.-H., Connolly, J., Shimasaki, N., Mimura, K., Kono, K., & Campana, D. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3558 · Cited by 329
Self-citationCarretero, M., Cantoni, C., Bellón, T., Bottino, C., Biassoni, R., Rodríguez, A., Pérez‐Villar, J. J., Moretta, L., Moretta, A., & López‐Botet, M. (1997) · European Journal of Immunology · doi:10.1002/eji.1830270230 · Cited by 281
de Kruijf, E. M., Sajet, A., van Nes, J. G. H., Natanov, R., Putter, H., Smit, V. T. H. B. M., Liefers, G. J., van den Elsen, P. J., van de Velde, C. J. H., & Kuppen, P. J. K. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1002629 · Cited by 266
Benson, D. M., Hofmeister, C. C., Padmanabhan, S., Suvannasankha, A., Jagannath, S., Abonour, R., Bakan, C., Andre, P., Efebera, Y., Tiollier, J., et al. (2012) · Blood · doi:10.1182/blood-2012-06-438028 · Cited by 244
Mingari, M. C., Ponte, M., Bertone, S., Schiavetti, F., Vitale, C., Bellomo, R., Moretta, A., & Moretta, L. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.3.1172 · Cited by 241
Shah, N. N., Baird, K., Delbrook, C. P., Fleisher, T. A., Kohler, M. E., Rampertaap, S., Lemberg, K., Hurley, C. K., Kleiner, D. E., Merchant, M. S., et al. (2015) · Blood · doi:10.1182/blood-2014-07-592881 · Cited by 238
Structural basis for NKG2A/CD94 recognition of HLA-E
Kaiser, B. K., Pizarro, J. C., Kerns, J. A., & Strong, R. K. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802736105 · Cited by 237
Cytotoxicity of Activated Natural Killer Cells against Pediatric Solid Tumors
Cho, D., Shook, D. R., Shimasaki, N., Chang, Y.-H., Fujisaki, H., & Campana, D. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0735 · Cited by 234
Self-citationStringaris, K., Sekine, T., Khoder, A., Alsuliman, A., Razzaghi, B., Sargeant, R., Pavlu, J., Brisley, G., de Lavallade, H., Sarvaria, A., et al. (2014) · Haematologica · doi:10.3324/haematol.2013.087536 · Cited by 231
Natural killer cell cytolytic activity is inhibited by NKG2-A and activated by NKG2-C
Houchins, J. P., Lanier, L. L., Niemi, E. C., Phillips, J. H., & Ryan, J. C. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.8.3603 · Cited by 229
Differential expression of HLA-E, HLA-F, and HLA-G transcripts in human tissue
Wei, X., & Orr, H. T. (1990) · Human Immunology · doi:10.1016/0198-8859(90)90076-2 · Cited by 225
NK Cell Terminal Differentiation: Correlated Stepwise Decrease of NKG2A and Acquisition of KIRs
Béziat, V., Descours, B., Parizot, C., Debré, P., & Vieillard, V. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011966 · Cited by 217
HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8+T lymphocytes
Gooden, M., Lampen, M., Jordanova, E. S., Leffers, N., Trimbos, J. B., van der Burg, S. H., Nijman, H., & van Hall, T. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1100354108 · Cited by 215
Imamura, M., Shook, D., Kamiya, T., Shimasaki, N., Chai, S. M. H., Coustan-Smith, E., Imai, C., & Campana, D. (2014) · Blood · doi:10.1182/blood-2014-02-556837 · Cited by 188
Self-citationPng, Y. T., Vinanica, N., Kamiya, T., Shimasaki, N., Coustan-Smith, E., & Campana, D. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017009928 · Cited by 187
Self-citationTargeting NK-cell checkpoints for cancer immunotherapy
Muntasell, A., Ochoa, M. C., Cordeiro, L., Berraondo, P., López-Díaz de Cerio, A., Cabo, M., López-Botet, M., & Melero, I. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2017.01.003 · Cited by 182
Malmberg, K.-J., Levitsky, V., Norell, H., Matos, C. T. D., Carlsten, M., Schedvins, K., Rabbani, H., Moretta, A., Söderström, K., Levitskaya, J., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15564 · Cited by 180
Analysis of HLA-E expression in human tumors
Marín, R., Ruiz-Cabello, F., Pedrinaci, S., Méndez, R., Jiménez, P., Geraghty, D. E., & Garrido, F. (2003) · Immunogenetics · doi:10.1007/s00251-002-0526-9 · Cited by 178
Derré, L., Corvaisier, M., Charreau, B., Moreau, A., Godefroy, E., Moreau-Aubry, A., Jotereau, F., & Gervois, N. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.5.3100 · Cited by 174
Nielsen, N., Ødum, N., Ursø, B., Lanier, L. L., & Spee, P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031959 · Cited by 172
Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells
Ruggeri, L., Urbani, E., Andre, P., Mancusi, A., Tosti, A., Topini, F., Blery, M., Animobono, L., Romagne, F., Wagtmann, N., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.135301 · Cited by 160
Miller, J. D., Weber, D., Ibegbu, C., Pohl, J., Altman, J., & Jensen, P. (2003) · Journal of Immunology · doi:10.4049/jimmunol.171.3.1369 · Cited by 154
The maturing role of COPI vesicles in intra-Golgi transport
Rabouille, C., & Klumperman, J. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1735 · Cited by 147
Mihara, K., Imai, C., Coustan‐Smith, E., Dome, J. S., Dominici, M., Vanin, E. F., & Campana, D. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04217.x · Cited by 143
Self-citationSheu, B., Chiou, S., Lin, H., Chow, S., Huang, S., Ho, H., & Hsu, S.-M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2108 · Cited by 141
Surrogate variable analysis using partial least squares (SVA-PLS) in gene expression studies
Chakraborty, S., Datta, S., & Datta, S. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts022 · Cited by 130
Harnessing NK Cell Memory for Cancer Immunotherapy
Fehniger, T. A., & Cooper, M. A. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.09.005 · Cited by 111
Retention mechanisms for ER and Golgi membrane proteins
Gao, C., Cai, Y., Wang, Y., Kang, B., Aniento, F., Robinson, D. G., & Jiang, L. (2014) · Trends in Plant Science · doi:10.1016/j.tplants.2014.04.004 · Cited by 110
Nguyen, S., Béziat, V., Dhédin, N., Kuentz, M., Vernant, J., Debré, P., & Vieillard, V. (2008) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.380 · Cited by 105
Therapeutic applications: natural killer cells in the clinic
Miller, J. S. (2013) · Hematology · doi:10.1182/asheducation-2013.1.247 · Cited by 96
Predictive value of HLA-G and HLA-E in the prognosis of colorectal cancer patients
Guo, Z., Lv, Y., Wang, L., Shi, S., Yang, F., Zheng, G., Wen, W., & Yang, A. (2014) · Cellular Immunology · doi:10.1016/j.cellimm.2014.10.003 · Cited by 95
Expanded and Activated Natural Killer Cells for Immunotherapy of Hepatocellular Carcinoma
Kamiya, T., Chang, Y.-H., & Campana, D. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0229 · Cited by 94
Self-citationExpanded and armed natural killer cells for cancer treatment
Shimasaki, N., Coustan‐Smith, E., Kamiya, T., & Campana, D. (2016) · Cytotherapy · doi:10.1016/j.jcyt.2016.06.013 · Cited by 90
Self-citationPende, D., Sivori, S., Accame, L., Pareti, L., Falco, M., Geraghty, D. E., Bouteiller, P. P. L., Moretta, L., & Moretta, A. (1997) · European Journal of Immunology · doi:10.1002/eji.1830270809 · Cited by 89
Sáez‐Borderías, A., Romo, N., Magri, G., Gumá, M., Angulo, A., & López‐Botet, M. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.2.829 · Cited by 82
Gustafson, K. S., & Ginder, G. D. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.33.20035 · Cited by 82
A novel method to generate T-cell receptor–deficient chimeric antigen receptor T cells
Kamiya, T., Wong, D., Png, Y. T., & Campana, D. (2018) · Blood Advances · doi:10.1182/bloodadvances.2017012823 · Cited by 81
Self-citationHLA-dependent tumour development: a role for tumour associate macrophages?
Marchesi, M., Andersson, E. K., Villabona, L. E. E., Seliger, B., Lundqvist, A., Kiessling, R. W., & Masucci, G. V. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-247 · Cited by 79
Manabe, A., Coustan‐Smith, E., KUMAGAI, M., Behm, F., Raimondi, S., Pui, C., & Campana, D. (1994) · Blood · doi:10.1182/blood.v83.7.1731.1731 · Cited by 78
Self-citationLung Tumor Microenvironment Induces Specific Gene Expression Signature in Intratumoral NK Cells
Gillard, M., Caer, C., Cagnard, N., Crozet, L., Perez, M., Fridman, W. H., Sautès‐Fridman, C., & Cremer, I. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00019 · Cited by 73
Andersson, E. K., Poschke, I. C., Villabona, L. E. E., Carlson, J. W., Lundqvist, A., Kiessling, R. W., Seliger, B., & Masucci, G. V. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1052213 · Cited by 73
Zhou, J., Matsuoka, M., Cantor, H., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.1.25 · Cited by 55
Silva, T. G., Crispim, J. C. O., Miranda, F. A., Hassumi, M. K., de Mello, J. M. Y., Simões, R. T., Souto, F. J. D., Soares, E. G., Donadi, E. A., & Soares, C. P. (2011) · PubMed · doi:10.14670/hh-26.1487 · Cited by 53
Das, J., & Khakoo, S. (2015) · Immunological Reviews · doi:10.1111/imr.12315 · Cited by 52
Malmberg, K., Sohlberg, E., Goodridge, J., & Ljunggren, H. (2017) · Immunogenetics · doi:10.1007/s00251-017-1011-9 · Cited by 37
Cited by
Zhang, Y., & Zhang, Z. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0488-6 · Cited by 2,794
NK cells for cancer immunotherapy
Shimasaki, N., Jain, A., & Campana, D. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0052-1 · Cited by 1,222
Self-citationNatural killer cells in cancer biology and therapy
Wu, S.-Y., Fu, T., Jiang, Y.-Z., & Shao, Z.-M. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01238-x · Cited by 863
Natural killer cells in antitumour adoptive cell immunotherapy
Laskowski, T. J., Biederstädt, A., & Rezvani, K. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00491-0 · Cited by 773
Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends
Sun, Q., Hong, Z., Zhang, C., Wang, L., Han, Z., & Ma, D. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01522-4 · Cited by 598
Metadata
- Authors
- Kamiya, T., Seow, S. V., Wong, D., Robinson, M., & Campana, D.
- Venue
- Journal of Clinical Investigation
- Published
- 2019-04-15
- Volume
- 129
- Issue
- 5
- Pages
- 2094-2106
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W2920927214
- Cited by
- 342
- References
- 79
- FWCI
- 12.42
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.